Mycophenolate mofetil

Theodore M. Sievers, Stephen J. Rossi, Rafik M. Ghobrial, Edgar Arriola, Pamela Nishimura, Marv Kawano, Curtis D. Holt

Research output: Contribution to journalReview articlepeer-review

113 Scopus citations


Mycophenolate mofetil is the morpholinoethylester prodrug of mycophenolic acid, an agent that inhibits the proliferation of B and T lymphocytes through noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, a key enzyme in the de novo synthetic pathway of guanine nucleotides. Currently, mycophenolate mofetil is approved for the prevention of acute renal allograft rejection when given in combination with cyclosporine and steroids. Several studies also demonstrated that the agent is effective in the treatment of refractory rejection in renal, heart, and liver transplant recipients, and may have efficacy in the treatment of chronic rejection as well.

Original languageEnglish (US)
Pages (from-to)1178-1197
Number of pages20
Issue number6
StatePublished - Nov 1 1997

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Mycophenolate mofetil'. Together they form a unique fingerprint.

Cite this